16 February 2022 - PHARMAC is releasing meeting records of its COVID-19 Treatments Advisory Group and seeking feedback on the patient access criteria for two COVID-19 anti-viral treatments – molnupiravir (Lagevrio) and nirmatrelvir and ritonavir (Paxlovid).
“To help us make decisions about COVID-19 treatments, we set up a COVID-19 Treatments Advisory Group,” says Dr David Hughes, Pharmac’s Chief Medical Officer. “They look at the evidence for these treatments, to help us understand how they could benefit New Zealanders.